Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

unknown150%
not_yet_recruiting150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

NCT06136988
unknownphase_2

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment

NCT01796288

Clinical Trials (2)

Showing 2 of 2 trials
NCT06136988Phase 1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not Yet Recruiting
NCT01796288Phase 2

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment

Unknown

All 2 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
2